Main description:

Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers' needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.

Key Features:

The first guide to market access for pharmaceuticals based on tested teaching materials
Addresses both pharmaceutical and vaccine products
Includes case studies and scenarios
Covers market access consdierations for Western Europe, the USA, Japan and China
Explains the impact the changing healthcare market will have on your product

Contents:

Chapter 1: Health as a Good

Chapter 2: Decision-Making in Public Health

Chapter 3: Definition and Concepts

Chapter 4: HTA Decision Analysis framework

Chapter 5: Early HTA Advice

Chapter 6: Overview of Market Access Agreements

Chapter 7: External Reference Pricing

Chapter 8: Gap between Payers and Regulators

Chapter 9: Early Access Programs

Chapter 10: Market Access of Orphan Drugs

Chapter 11: Market Access of Vaccines in Developed Countries

Chapter 12: France

Chapter 13: Germany

Chapter 14: Italy

Chapter 15: Spain

Chapter 16: Sweden

Chapter 17: United Kingdom

Chapter 18: The United States

Chapter 19: Japan

Chapter 20: China